FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891925600> ?p ?o ?g. }

• W2891925600 endingPage "2542" @default.
• W2891925600 startingPage "2530" @default.
• W2891925600 abstract "Abstract Tumors use indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is induced in response to inflammatory stimuli such as IFNγ and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites, including kynurenine, in the tumor microenvironment. This leads to effector T-cell anergy and enhanced Treg function through upregulation of FoxP3. As a nexus for the induction of key immunosuppressive mechanisms, IDO1 represents an important immunotherapeutic target in oncology. Here, we report the identification and characterization of the novel selective, orally bioavailable IDO1 inhibitor EOS200271/PF-06840003. It reversed IDO1-induced T-cell anergy in vitro. In mice carrying syngeneic tumor grafts, PF-06840003 reduced intratumoral kynurenine levels by over 80% and inhibited tumor growth both in monotherapy and, with an increased efficacy, in combination with antibodies blocking the immune checkpoint ligand PD-L1. We demonstrate that anti–PD-L1 therapy results in increased IDO1 metabolic activity thereby providing additional mechanistic rationale for combining PD-(L)1 blockade with IDO1 inhibition in cancer immunotherapies. Supported by these preclinical data and favorable predicted human pharmacokinetic properties of PF-06840003, a phase I open-label, multicenter clinical study (NCT02764151) has been initiated." @default.
• W2891925600 created "2018-09-27" @default.
• W2891925600 creator A5000804175 @default.
• W2891925600 creator A5002197682 @default.
• W2891925600 creator A5003715910 @default.
• W2891925600 creator A5006856205 @default.
• W2891925600 creator A5013106114 @default.
• W2891925600 creator A5016938641 @default.
• W2891925600 creator A5018323071 @default.
• W2891925600 creator A5020133148 @default.
• W2891925600 creator A5022553469 @default.
• W2891925600 creator A5024323910 @default.
• W2891925600 creator A5032888152 @default.
• W2891925600 creator A5035122235 @default.
• W2891925600 creator A5042409986 @default.
• W2891925600 creator A5045307657 @default.
• W2891925600 creator A5047357717 @default.
• W2891925600 creator A5058059268 @default.
• W2891925600 creator A5058150315 @default.
• W2891925600 creator A5059897477 @default.
• W2891925600 creator A5063500857 @default.
• W2891925600 creator A5071409456 @default.
• W2891925600 creator A5071595199 @default.
• W2891925600 creator A5075323544 @default.
• W2891925600 creator A5075849487 @default.
• W2891925600 creator A5079880890 @default.
• W2891925600 creator A5081427242 @default.
• W2891925600 creator A5084946547 @default.
• W2891925600 creator A5087148709 @default.
• W2891925600 creator A5091214474 @default.
• W2891925600 date "2018-12-01" @default.
• W2891925600 modified "2023-10-17" @default.
• W2891925600 title "Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy" @default.
• W2891925600 cites W1505072916 @default.
• W2891925600 cites W1603640418 @default.
• W2891925600 cites W1913780655 @default.
• W2891925600 cites W1942897646 @default.
• W2891925600 cites W1973251492 @default.
• W2891925600 cites W1975929837 @default.
• W2891925600 cites W1991075838 @default.
• W2891925600 cites W1991344565 @default.
• W2891925600 cites W2007489575 @default.
• W2891925600 cites W2008343182 @default.
• W2891925600 cites W2010378562 @default.
• W2891925600 cites W2022430924 @default.
• W2891925600 cites W2024000351 @default.
• W2891925600 cites W2038234028 @default.
• W2891925600 cites W2072078248 @default.
• W2891925600 cites W2087801719 @default.
• W2891925600 cites W2103553504 @default.
• W2891925600 cites W2104065243 @default.
• W2891925600 cites W2113325722 @default.
• W2891925600 cites W2113846910 @default.
• W2891925600 cites W2113906692 @default.
• W2891925600 cites W2122285073 @default.
• W2891925600 cites W2126932404 @default.
• W2891925600 cites W2127903252 @default.
• W2891925600 cites W2134670672 @default.
• W2891925600 cites W2167897482 @default.
• W2891925600 cites W2298272175 @default.
• W2891925600 cites W2418696831 @default.
• W2891925600 cites W2553568639 @default.
• W2891925600 cites W2570766240 @default.
• W2891925600 cites W2589004473 @default.
• W2891925600 cites W2599400888 @default.
• W2891925600 cites W2741622689 @default.
• W2891925600 cites W2767640831 @default.
• W2891925600 doi "https://doi.org/10.1158/1535-7163.mct-17-1104" @default.
• W2891925600 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30232146" @default.
• W2891925600 hasPublicationYear "2018" @default.
• W2891925600 type Work @default.
• W2891925600 sameAs 2891925600 @default.
• W2891925600 citedByCount "54" @default.
• W2891925600 countsByYear W28919256002019 @default.
• W2891925600 countsByYear W28919256002020 @default.
• W2891925600 countsByYear W28919256002021 @default.
• W2891925600 countsByYear W28919256002022 @default.
• W2891925600 countsByYear W28919256002023 @default.
• W2891925600 crossrefType "journal-article" @default.
• W2891925600 hasAuthorship W2891925600A5000804175 @default.
• W2891925600 hasAuthorship W2891925600A5002197682 @default.
• W2891925600 hasAuthorship W2891925600A5003715910 @default.
• W2891925600 hasAuthorship W2891925600A5006856205 @default.
• W2891925600 hasAuthorship W2891925600A5013106114 @default.
• W2891925600 hasAuthorship W2891925600A5016938641 @default.
• W2891925600 hasAuthorship W2891925600A5018323071 @default.
• W2891925600 hasAuthorship W2891925600A5020133148 @default.
• W2891925600 hasAuthorship W2891925600A5022553469 @default.
• W2891925600 hasAuthorship W2891925600A5024323910 @default.
• W2891925600 hasAuthorship W2891925600A5032888152 @default.
• W2891925600 hasAuthorship W2891925600A5035122235 @default.
• W2891925600 hasAuthorship W2891925600A5042409986 @default.
• W2891925600 hasAuthorship W2891925600A5045307657 @default.
• W2891925600 hasAuthorship W2891925600A5047357717 @default.
• W2891925600 hasAuthorship W2891925600A5058059268 @default.
• W2891925600 hasAuthorship W2891925600A5058150315 @default.
• W2891925600 hasAuthorship W2891925600A5059897477 @default.
• W2891925600 hasAuthorship W2891925600A5063500857 @default.

• next